INNV vs. NHC, AGL, FTRE, CDNA, VRDN, AHCO, PNTG, AVAH, CSTL, and TALK
Should you be buying InnovAge stock or one of its competitors? The main competitors of InnovAge include National HealthCare (NHC), agilon health (AGL), Fortrea (FTRE), CareDx (CDNA), Viridian Therapeutics (VRDN), AdaptHealth (AHCO), The Pennant Group (PNTG), Aveanna Healthcare (AVAH), Castle Biosciences (CSTL), and Talkspace (TALK). These companies are all part of the "healthcare" industry.
InnovAge vs.
InnovAge (NASDAQ:INNV) and National HealthCare (NYSE:NHC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations.
InnovAge currently has a consensus target price of $5.00, indicating a potential upside of 50.60%. Given InnovAge's stronger consensus rating and higher probable upside, analysts clearly believe InnovAge is more favorable than National HealthCare.
National HealthCare received 2 more outperform votes than InnovAge when rated by MarketBeat users. Likewise, 100.00% of users gave National HealthCare an outperform vote while only 0.00% of users gave InnovAge an outperform vote.
12.3% of InnovAge shares are held by institutional investors. Comparatively, 56.4% of National HealthCare shares are held by institutional investors. 1.4% of InnovAge shares are held by insiders. Comparatively, 13.8% of National HealthCare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, National HealthCare had 2 more articles in the media than InnovAge. MarketBeat recorded 2 mentions for National HealthCare and 0 mentions for InnovAge. National HealthCare's average media sentiment score of 0.01 beat InnovAge's score of 0.00 indicating that National HealthCare is being referred to more favorably in the news media.
National HealthCare has a net margin of 10.03% compared to InnovAge's net margin of -3.19%. National HealthCare's return on equity of 6.87% beat InnovAge's return on equity.
National HealthCare has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than National HealthCare, indicating that it is currently the more affordable of the two stocks.
InnovAge has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, National HealthCare has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.
Summary
National HealthCare beats InnovAge on 15 of the 17 factors compared between the two stocks.
Get InnovAge News Delivered to You Automatically
Sign up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InnovAge Competitors List
Related Companies and Tools
This page (NASDAQ:INNV) was last updated on 2/22/2025 by MarketBeat.com Staff
